Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
References
Innovation: Clinical trials
Abbreviations
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
sabatolimab - TIM3 antagonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03946670 STIMULUS MDS-1 (CMBG453B12201)
Myelodysplastic syndrome
Phase 2
120
Complete Remission (CR) rate and Progression Free Survival (PFS)
Experimental: Sabatolimab (MBG453) + hypomethylating agents
Placebo comparator: Placebo + hypomethylating agents
Adult subjects with intermediate, high or very high risk Myelodysplastic Syndrome
(MDS) as per IPSS-R criteria
Target Patients
Read-out Milestone(s)
2022-2023
Publication
TBD
NCT04150029 STIMULUS-AML1 (CMBG453C12201)
Unfit acute myeloid leukaemia
Phase 2
86
Incidence of dose limiting toxicities (Safety run-in patients only)
Percentage of subjects achieving complete remission (CR)
Single arm safety and efficacy study of sabatolimab in combination with azacitidine
and venetoclax
Newly diagnosed adult AML patients who are not suitable for treatment with
intensive chemotherapy
2023
TBD
112 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation